Lexicon Financial Results and Business Update

 

• Commercial launch of INPEFA^® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community
• Significant formulary inclusions effective in Q4 opening the opportunity for further commercial acceleration into 2024 and beyond
• LX9211 moving into late-stage development for the treatment of diabetic peripheral neuropathic pain
• Conference Call and Webcast at 8:00 am Eastern Time

Lexicon management will hold a live conference call and webcast today at 8:00 am ET / 7:00 am CT to review its financial and operating results and to provide a general business update. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 2598226. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.

https://www.biospace.com/article/releases/lexicon-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-business-update/